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Functional redundancy between Apc and Apc2 regulates tissue
homeostasis and prevents tumorigenesis in murine mammary
epithelium
CS Daly1, P Shaw1, LD Ordonez1, GT Williams2, J Quist3,4, A Grigoriadis3,4, JH Van Es5, H Clevers5, AR Clarke1 and KR Reed1
Aberrant Wnt signaling within breast cancer is associated with poor prognosis, but regulation of this pathway in breast tissue
remains poorly understood and the consequences of immediate or long-term dysregulation remain elusive. The exact contribution
of the Wnt-regulating proteins adenomatous polyposis coli (APC) and APC2 in the pathogenesis of human breast cancer are ill-
deﬁned, but our analysis of publically available array data sets indicates that tumors with concomitant low expression of both
proteins occurs more frequently in the ‘triple negative’ phenotype, which is a subtype of breast cancer with particularly poor
prognosis. We have used mouse transgenics to delete Apc and/or Apc2 from mouse mammary epithelium to elucidate the
signiﬁcance of these proteins in mammary homeostasis and delineate their inﬂuences on Wnt signaling and tumorigenesis. Loss of
either protein alone failed to affect Wnt signaling levels or tissue homeostasis. Strikingly, concomitant loss led to local disruption of
β-catenin status, disruption in epithelial integrity, cohesion and polarity, increased cell division and a distinctive form of ductal
hyperplasia with ‘squamoid’ ghost cell nodules in young animals. Upon aging, the development of Wnt activated mammary
carcinomas with squamous differentiation was accompanied by a signiﬁcantly reduced survival. This novel Wnt-driven mammary
tumor model highlights the importance of functional redundancies existing between the Apc proteins both in normal homeostasis
and in tumorigenesis.
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INTRODUCTION
Breast cancer is one of the commonest malignancies in the
Western world, accounting for a ﬁfth of all deaths from cancer in
women. Dysregulation of the Wnt signaling pathway is a frequent
event in human cancers1 and has been associated with both
breast cancer initiation2 and progression.3 The canonical Wnt
pathway is multifaceted (reviewed in Clevers and Nusse4), but
central to it is β-catenin, which acts as an intracellular signal
transducer. Elevated expression, reduced membrane association
and activation of β-catenin have been reported in human breast
cancers and are associated with poor patient prognosis.3,5–11
However, pathway mutations are rare,5,6 and dysregulation most
likely occurs because of subtle perturbation of the protein
localization or through epigenetic means.
Both adenomatous polyposis coli (APC) and APC2 can regulate
β-catenin/Wnt signaling12–14 and both are expressed in human
mammary epithelium.15–17 Reduction of APC through loss of
heterozygosity,15,18 promoter hypermethylation16,19–22 and
somatic mutation23 has been reported in breast cancers. Reduced
APC2 has also been implicated in breast cancer through loss of
heterozygosity,24–26 allelic imbalance17 and promoter hyper-
methylation.27 As both APC proteins can regulate Wnt signaling,
both are expressed in mammary epithelium and loss of either has
been linked with breast cancer, there is a possibility that
functional redundancies exist in this tissue as they do in
Drosophila development,28 but this has yet to be proven. Here,
through the use of mouse transgenics, we show that concomitant
loss of both mammary Apc proteins induces an aberrant
hyperplastic phenotype in young mice that progresses with time
into Wnt-driven tumors. These experiments underscore the
importance of functional redundancies between the Apc proteins
and present a useful Wnt-driven mammary tumor model.
RESULTS
The normal expression proﬁle of both Apc and Apc2 in the
mammary epithelium can be disrupted through the use of
transgenic mouse models
Comprehensive loss of Apc2 within mammary epithelium occurs
in mice harboring a constitutive homozygous Apc2 mutation
(Apc2−/−)29 (Figure 1a), facilitating the exploration of the role of
Apc2 in this tissue. Cre/loxP transgenesis utilizing Blg-Cre+ and
Apcﬂ/ﬂ alleles, (a transgenic combination used previously),30
facilitates mammary epithelial-speciﬁc loss of Apc while circum-
venting embryonic lethality associated with constitutive Apc
loss.31 Cre-mediated recombination in virgin mammary glands
occurs in a heterogeneous manner, determined using 10-week-old
glands from Blg-Cre+ mice crossed with the ROSA26 reporter strain
(Supplementary Figure 1). β-Galactosidase ﬂuorescent immuno-
histochemical (IHC) analysis corroborated a heterogeneous
recombination pattern, occurring primarily in luminal cells
(Figure 1b). Note, the level of recombination is higher than 7%
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of cells as stated by Selbert et al.,32 but in line with other studies
using this Cre.30,33 Apc IHC conﬁrmed both the presence of Apc in
Blg-CrenegativeApcﬂ/ﬂ epithelium and the expected heterogeneous
pattern of loss in Blg-Cre+Apcﬂ/ﬂ glands (Figure 1c). Together these
results show that both Apc proteins are normally present in
mammary epithelium and both can be disrupted through our
selected transgenic models.
The combined disruption of both Apc and Apc2 leads to epithelial
disruption, hyperplasia and lactation defects
Examination of 10-week-old virgin mammary glands (nX 3)
from four cohorts (wild type (termed Wt hereafter), Apc2−/−,
Blg-Cre+Apcﬂ/ﬂ and Blg-Cre+Apcﬂ/ﬂApc2−/−) revealed that while
either Apc2 or Apc alone were dispensable for mammary
epithelial integrity, combined loss led to a range of epithelial
defects (Figure 2). Carmine alum-stained glands revealed an
epithelial thickening, reduced branching and disruption of
epithelial structure, in 100% of Blg-Cre+Apcﬂ/ﬂApc2−/−glands
(Figures 2a–c). Furthermore, Blg-Cre+Apcﬂ/ﬂApc2−/−glands dis-
played an unusual and distinctive form of ductal epithelial
hyperplasia with prominent intraluminal, papillary, anucleate
‘ghost cell’ nodules, some of which underwent dislocation into
the peri-ductal stroma (Supplementary Figure 2). Many of these
ghost cell nodules had a ‘squamoid’ appearance, although other
markers of squamous differentiation such as intercellular prickles
Figure 1. Deletion of the Apc proteins from murine mammary epithelium. (a) Mammary gland sections from Apc2+/+ and Apc2−/− mice were
labeled for Apc2 using ﬂuorescent IHC. Although Apc2 is expressed in Wt epithelium, Apc2−/− glands displayed comprehensive Apc2 loss
(scale bar, 50 μm). (b) Virgin mammary gland sections from 10-week-old Blg-Cre+Rosa26+ mice were labeled for β-galactosidase to assess Cre-
mediated recombination. Recombination occurred in a heterogeneous manner, primarily within luminal cells (white arrowheads) but
occasionally detectable in apparent non-luminal cells (gray arrowhead) (scale bar, 25 μm). (c) Labeling of Virgin mammary glands section from
10-week-old Blg-Cre+Apcﬂ/ﬂ mice for Apc using ﬂuorescent IHC revealed a heterogeneous pattern of loss in epithelial cells (scale bar, 50 μm in
main image, 25 μm in inlay).
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(desmosomes) or keratin formation were not evident. Such ghost
cell nodules have previously been seen following Apc
inactivation,30 although their nature remains unclear. Although
this form of epithelial change is not recorded in human breast
pathology, the phenomenon of ghost cells (or ‘shadow’ cells) is
well recognized in certain other human tumors with ‘squamoid’
features, notably pilomatricomas, craniopharyngiomas and odon-
tomes, where it may be accompanied by expression of so-called
hard keratins34 and, importantly in the context of our ﬁndings,
aberrant β-catenin localization.34,35
Rates of cell turnover are normally relatively low in the
mammary epithelium.36 However, mitotic ﬁgures were readily
observable in Blg-Cre+Apcﬂ/ﬂApc2−/−epithelium while seldom seen
in other genotypes. The hyperplastic phenotype was conﬁrmed by
a statistically signiﬁcant increase in Ki-67 labeled nuclei (Figure 2d)
in Blg-Cre+Apcﬂ/ﬂApc2−/−mammary epithelium compared with all
other genotypes. Interestingly, Apc2−/− displayed a signiﬁcant
decrease in proliferation compared with Wt mammary epithelium.
Anti-cleaved caspase-3 IHC demonstrated that while cell death
was seldom observed in Wt epithelium or in the single knock-out
Figure 2. Either Apc or Apc2 is dispensable, however, concurrent loss results in a range of epithelial disruptions. (a) Carmine alum-stained
whole mount glands from 10-week-old virgin mice reveals that loss of either Apc protein alone is tolerated, whereas combined loss results in
severe defects in ductal branching and epithelial thickening (scale bar, 200 um). (b) Quantiﬁcation of ductal branching. (c) Quantiﬁcation of
epithelial thickening. (d) H&E-stained sections of mammary tissue from each genotype reveal epithelial disruptions with intraluminal ghost
cell nodules in glands deﬁcient for both Apc proteins (Blg-Cre+Apcﬂ/ﬂApc2−/−) (scale bar, 50 μm). Labeling for both Ki-67 and caspase-3 exposed
an increase in positive cells in epithelium deﬁcient for both Apc proteins (arrows indicate positively labeled cells, scale bar, 50 μm). H&E-
stained sections of lactating glands from each genotype revealed Apc2-deﬁcient glands to be indistinguishable from Wt, Blg-Cre+Apcﬂ/ﬂ glands
displayed attenuated alveolar formation with occasional ghost cell nodules (arrow) and Blg-Cre+Apcﬂ/ﬂApc2−/−glands displayed a complete lack
of differentiated alveoli and vastly perturbed tissue architecture (scale bar, 50 μm). (e) Quantiﬁcation of Ki-67-positive cells revealed a
reduction in proliferation in Apc2−/− compared with Wt epithelium. A statistical increase was noticed in epithelium deﬁcient for both Apc
proteins versus all other genotypes (error bars, s.d., *Pp 0.05 versus Wt, **Pp 0.01 versus all other genotypes, Mann–Whitney U-test, nX 3).
(f) Quantiﬁcation of caspase-3-positive cells revealed a statistical increase in apoptosis in epithelium deﬁcient for both Apc proteins (error
bars= s.d., **Pp 0.001 versus all other genotypes, Mann–Whitney U-test, nX 3). (g) Sections of 10-week-old virgin glands from Blg-Cre+Apcﬂ/ﬂ
and Blg-Cre+Apcﬂ/ﬂApc2−/−were double labeled for cytokeratin 8 (CK8, luminal cell marker) and cytokeratin 5 (CK5, myoepithelial cell marker).
In mammary epithelium deﬁcient for both Apc proteins, cells are organized haphazardly indicating disruptions in polarity (scale bar, 50 μm).
(h) Sections from these genotypes were also labeled for markers of polarity. Zo-1 staining is almost completely lost along with cells that also
display disruptions in E-cadherin (scale bar, 50 μm).
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tissue, there was a statistical increase in labeled cells
that extended into the ghost cell nodules in Blg-Cre+Apcﬂ/ﬂ
Apc2−/−glands (Figures 2d and e).
Females from each genotype were mated with stud males to
induce pregnancy. Following birth, all mothers and litters
displayed normal suckling behavior regardless of genotype.
However, although pups from Wt and Apc2−/− mothers were
indistinguishable, in agreement with other studies, pups from Blg-
Cre+Apcﬂ/ﬂ failed to thrive.30 Additional loss of Apc2 accentuated
this ﬁnding, whereby all pups from Blg-Cre+Apcﬂ/ﬂApc2−/−mothers
either died or had to be cross-fostered by 5 days postpartum. Lack
of observable milkspots in offspring in conjunction with normal
suckling behavior suggested lactation defects. Histological exam-
ination of lactating mammary glands 5 days postpartum
(Figure 2d) revealed that while Wt and Apc2−/− glands both
displayed fully differentiated milk-producing alveoli and were
indistinguishable, Blg-Cre+Apcﬂ/ﬂ glands, as previously reported,30
displayed occasional intraluminal ghost cell nodules and margin-
ally perturbed alveolar formation, although milk production was
still conspicuous. Contrary to this, differentiated alveoli were
completely absent from Blg-Cre+Apcﬂ/ﬂApc2−/−glands and tissue
architecture was perturbed with disorganized ductular structures
containing occasional densely eosinophilic luminal deposits.
Together these results show that the Apc proteins have a
functionally redundant role in the control of the differentiation
of mammary epithelium into milk-producing alveoli essential for
lactation.
Cellular positioning within the epithelia is perturbed following
disruption of both Apc proteins
Given that virgin Apc2−/− and Blg-Cre+Apcﬂ/ﬂ mammary glands
appear indifferent from Wt, subsequent analyses were performed
between virgin Blg-Cre+Apcﬂ/ﬂApc2−/−and Blg-Cre+Apcﬂ/ﬂ glands to
compare the effects of additional Apc2 loss in the context of Apc
deletion.
Cytokeratin 8 (luminal cell marker) and cytokeratin 5 (myoe-
pithelial cell marker) staining (Figure 2g) demonstrates well
organized and highly polarized cells within the Blg-Cre+Apcﬂ/ﬂ
epithelium, consistent with that observed in Wt tissue.37 Contrary
to this, Blg-Cre+Apcﬂ/ﬂApc2−/−glands displayed a severe disruption
to the normal organization, and a haphazard localization of
luminal and basal (myoepithelial) cells suggesting a loss
of positional identity. E-cadherin is the principal component of
adherens junctions involved in cell–cell adhesion (reviewed in
Gumbiner38), whereas Zo-1 is a component of tight junctions
critical for maintaining barrier function.39 Together Zo-1 and
E-cadherin have been shown to colocalize with β-catenin at the
plasma membrane during the formation of the adherens and tight
junctions, to co-immunoprecipitate,40 and to help establish and
maintain epithelial polarity.41 Blg-Cre+Apcﬂ/ﬂ epithelium maintains
Zo-1 in the normal apical position and E-cadherin at a position
consistent with cell–cell contacts (Figure 2h). By contrast, Zo-1 is
virtually absent from Blg-Cre+Apcﬂ/ﬂApc2−/−epithelium, and there
are occasional patches of cells displaying reduced levels of
E-cadherin (Figure 2h). The mechanisms through which Zo-1 is lost
in the Blg-Cre+Apcﬂ/ﬂApc2−/−epithelium requires further investiga-
tion, although it is possible that aberrant β-catenin localization
and Wnt activation in the Blg-Cre+Apcﬂ/ﬂApc2−/−mammary gland
could contribute to the observed defects in positioning and
adhesion. Activation of the Wnt signal pathway and nuclear
translocation of β-catenin can suppress Zo-1 and E-cadherin
activity, diminishing polarity,42,43 whereas nuclear translocation of
β-catenin and subsequent Wnt activation can promote reductions
in cell adhesion.44,45 However, it is clear that these results show
functional redundancies between the Apc proteins in the
maintenance of normal cellular positioning.
Combined disruption of both Apc and Apc2 leads to deregulated
β-catenin status in a subset of epithelial cells
Both Apc proteins share the ability to mediate Wnt signaling
through β-catenin degradation,1,12–14,46 whereas activating
β-catenin mutations have been reported to induce mammary
gland hyperplasia.47,48 Analysis of β-catenin status (Figure 3a)
shows that β-catenin in Blg-Cre+Apcﬂ/ﬂ epithelium, akin to Wt,
displays a cytoplasmic and membrane bound expression pattern
with the highest levels detected on the apical surface in a
polarized manner. Conversely, in Blg-Cre+Apcﬂ/ﬂApc2−/−glands the
β-catenin staining pattern is disrupted in a heterogeneous
manner, ranging from loss and mis-localization of β-catenin
expression in some clusters of cells (Figure 3a-iv) to, areas
displaying upregulation and classical nuclear β-catenin staining in
some cell clusters (Figure 3a-iii). Interestingly, nuclear localization
of β-catenin was often found in epithelial cells at the periphery of
the ghost cell nodules (Supplementary Figure 2B), and aberrant
β-catenin localization and activation leading to ‘squamoid’
transdifferentiation may well explain the presence of ghost cells
in the Blg-Cre+Apcﬂ/ﬂApc2−/−glands.
IHC analysis for Apc, β-catenin, cMyc and CD44 on serial
sections of mammary glands from each genotype (Figure 3b)
conﬁrmed that loss of Apc2 or Apc alone does not induce
detectable changes in β-catenin localization or expression of the
Wnt targets cMyc or CD44. It is pertinent to note that loss of Apc is
not uniform even within the apparent areas aberrant morphology,
with some cells maintaining expression of Apc (Figure 3b).
However, increased staining intensity of β-catenin, along with
nuclear translocation in a subset of cells could be detected in Blg-
Cre+Apcﬂ/ﬂApc2−/−tissue. Furthermore, expression of cMyc was also
detectable in a subset of cells within Blg-Cre+Apcﬂ/ﬂApc2−/−tissue
(Supplementary Figure 2C), suggestive of Wnt signaling activation,
although CD44 changes remained undetectable. Thus, the pattern
of changes is complex and does not lead to uniform activation of
the Wnt pathway in all cells. The nature of Cre recombination in
our model may account for the heterogeneous pattern of
β-catenin staining, as it is possible that variations could arise as
a consequence of Apc loss in different epithelial sub-populations.
Alternately, the variations in β-catenin may represent different
stages following the combined loss of the Apc proteins, but taken
together, these results show that disruption of both Apc proteins
results in aberrant β-catenin status within the mammary
epithelium.
Disruption of Apc and Apc2 results in tumor formation
The long-term consequences of loss of mammary epithelial Apc
proteins were analyzed in cohorts of Wt, Apc2−/−, Blg-Cre+Apcﬂ/ﬂ,
Blg-Cre+Apcﬂ/ﬂ Apc2+/- and Blg-Cre+Apcﬂ/ﬂApc2−/− mice that were
aged and killed on signs of ill health. Mice deﬁcient for Apc2 or
Apc alone displayed no differences in survival from Wt; however,
the Blg-Cre+Apcﬂ/ﬂApc2+/- and Blg-Cre+Apcﬂ/ﬂApc2−/−cohorts dis-
played a signiﬁcantly reduced survival (Figure 4a). A reduction in
survival in the Blg-Cre+Apcﬂ/ﬂApc2−/−compared with Blg-Cre+Apcﬂ/
ﬂApc2+/- mice indicated an Apc2 gene dose-dependent effect in
the context of Apc loss. Furthermore, although Wt, Apc2−/− or Blg-
Cre Apcﬂ/ﬂ mice displayed no signs of mammary pathology, 46% of
Blg-Cre+Apcﬂ/ﬂApc2+/- mice (6 of 13) and 80% of Blg-Cre+Apcﬂ/
ﬂApc2−/−mice (8 of 10) presented with tumors in one or more
mammary gland at the time of death (Figure 4b). The epithelial
integrity within 10-week-old Blg-Cre+Apcﬂ/ﬂApc2+/- glands is similar
to Blg-Cre+Apcﬂ/ﬂApc2−/−mice (Supplementary Figure 3), although
the severity was somewhat reduced, conﬁrming a gene dose-
dependent effect of Apc2 in the context of Apc mutation. It should
be remembered that while APC2 mutation is infrequent, gene
silencing through varying degrees of promoter hypermethylation
is extremely common in human breast cancers.2 Levels of
promoter methylation correlate with levels of reduced protein
Apc and Apc2 in mammary gland tumorigenesis
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expression.2,49 These observations imply that reduced expression
levels of APC2 are sufﬁcient for tumorigenesis in the appropriate
context.
Histological analysis of mammary tissue harvested from aged
mice at the time of death conﬁrmed the presence of tumors solely
within Blg-Cre+Apcﬂ/ﬂApc2+/- and Blg-Cre+Apcﬂ/ﬂApc2−/−mice
(Figure 4c) although, in agreement with previous studies,30
occasional small clusters of ghost cells were present in Blg-
Cre+Apcﬂ/ﬂ glands. The breast tumors in both the Blg-Cre+
Apcﬂ/ﬂApc2+/- and Blg-Cre+Apcﬂ/ﬂApc2−/−mice displayed squamous
Figure 3. Apc proteins are functionally redundant in control of β-catenin status. (a) Sections of Blg-Cre+Apcﬂ/ﬂ and Blg-Cre+Apcﬂ/ﬂApc2−/
−mammary glands were labeled for β-catenin using ﬂuorescent IHC to assess the status of this intracellular Wnt transducer. (i) Epithelium
deﬁcient for Apc alone retained a cytoplasmic and membrane associated staining pattern of β-catenin. Staining was at its highest intensity
toward the apical surface in a polarized manner. (ii–v) In mammary tissue deﬁcient for both Apc proteins, epithelial β-catenin was disrupted.
Certain areas displayed (ii) mis-localized, (iii) strong nuclear or (iv) absent epithelial β-catenin staining. (v) Ghost cells display no DAPI or β-
catenin staining (scale bar, 50 μm in top image, 25 μm in i–v). (b) Serial sections of mammary epithelium from each genotype were labeled for
Apc, β-catenin, cMyc and CD44. Inactivation of either Apc protein alone did not induce changes in β-catenin localization or status of Wnt
targets. Combined loss induced upregulation and nuclear translocation of β-catenin and activated expression of the Wnt target gene cMyc.
CD44 expression was undetectable in any genotype (red arrow indicates area deﬁcient for Apc, scale bar, 50 μm).
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differentiation. They were both proliferative and invasive and
were classiﬁed as well differentiated squamous carcinoma
(Supplementary Figure 4). Metastasis to distant sites was not
observed.
IHC analysis of the Wnt pathway in harvested tumors (Figure 5)
demonstrated a heterogeneous pattern of cMyc, CD44 and
nuclear β-catenin staining, although areas of nuclear or upregu-
lated β-catenin also displayed increased cMyc expression in serial
sections. Overexpression of cMyc, a global regulator of
transcription50 and a known Wnt target gene,51 has previously
been reported to induce mammary carcinomas in mice52 and
found to be overexpressed in the majority of human
breast tumors.53 Given Wnt pathway activation was only
apparent in a subset of epithelial cells at an early time point, it
is unclear whether these tumors arise because of Wnt activation in
speciﬁc cell types, which one could speculate to be mammary
stem cells or because of accumulation of other oncogenic
mutations.
Taken together, therefore, our results show that the concomi-
tant loss of both Apc proteins within mammary epithelium results
in epithelial hyperplasia with squamoid ghost cell features at an
early age, followed by the development of carcinomas showing
squamous differentiation in aged mice, which is consistent with
neoplastic progression.
APC and APC2 copy number in human breast cancer
To address the relevance of APC and APC2 in human breast cancer,
we interrogated primary invasive ductal carcinomas from the
publically available METABRIC54 and TCGA BRCA55 cohorts. From
the 1381 primary breast tumors in METABRIC, loss (copy number
o2) of APC, located on 5q22.2, was observed in 96 (6.9%) and loss
of APC2 on 19p13.3 in 118 (8.5%). In 54 (3.9%) samples, the
genomic regions encompassing APC and APC2 were lost. In the
965 TCGA breast cancer samples, the genomic APC regions was
lost in 108 samples (11.3%), APC2 in 91 (9.5%) and concurrent loss
of APC and APC2 was seen in 35 (3.7%) of samples. Next, we asked
whether concurrent loss of APC and APC2 was breast cancer
subtype speciﬁc and detected an enrichment of dual loss for
triple-negative breast cancers (Fisher’s exact test two tailed
Po0.0001 in both data sets) (Figure 6a). In addition, loss of
APC and APC2 results in increased expression of the Wnt signaling
Figure 4. Functional redundancies exist between Apc proteins in tumor suppression. (a) Wt (yellow line), Apc2−/−(purple line), Blg-Cre+Apcﬂ/ﬂ
(blue line), Blg-Cre+Apcﬂ/ﬂApc2+/− (green line) and Blg-Cre+Apcﬂ/ﬂApc2−/− (red line) mice were aged and culled upon signs of ill health (Kaplan–
Meier survival curves). Apc2−/− and Blg-Cre+Apcﬂ/ﬂ mice displayed no differences in survival compared with Wt mice (log-rank test, P40.32,
nX 11). Both Blg-Cre+Apcﬂ/ﬂApc2+/- and Blg-Cre+Apcﬂ/ﬂApc2−/− mice displayed reduced survival compared with other genotypes (asterisks mark
statistically different comparisons, Pp 0.01, log-rank test, nX 11). (b) Mice were examined at time of death. Although Wt, Apc2−/− and Blg-
Cre+Apcﬂ/ﬂ mice displayed no signs of mammary pathology, 46% of Blg-Cre+Apcﬂ/ﬂ Apc2+/- and 80% of Blg-Cre+Apcﬂ/ﬂApc2−/− mice exhibited
mammary tumors. (c) Representative images of H&E-stained mammary gland sections taken from aged mice. No lesions were found in Wt,
Apc2−/− or Blg-Cre+Apcﬂ/ﬂ glands, however, small infrequent intraductal aggregates of ghost cells were present in Blg-Cre+Apcﬂ/ﬂ tissue (arrow).
The majority of mammary tumors from Blg-Cre+Apcﬂ/ﬂ Apc2+/- and Blg-Cre+Apcﬂ/ﬂApc2−/− mice were classiﬁed as invasive carcinomas with
squamous differentiation (scale bar, 1mm).
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target genes cMYC and Sox9 (Figure 6b), lending further
weight to the clinical relevance of the loss of both genes,
especially for a difﬁcult to treat sub-population of human cancer
patients.
To interrogate overall survival of breast cancer patients with
concurrent APC and APC2 loss, we performed Kaplan–Meier
survival analyses in the METABRIC breast cancer cohort. The
analysis demonstrates that patients with loss of either APC or APC2
display a reduced survival compared with patients with ‘no loss’,
although survival of patients with loss of both APC and APC2
genes do not signiﬁcantly differ to APC loss alone, suggesting that
a synergistic affect between the two proteins does not exist with
respect to survival (Figure 6c).
DISCUSSION
In this study, we have assessed the functional redundancies
between the Apc proteins in mammary epithelium and their
roles in regulating Wnt transduction, tissue homeostasis and
tumor formation. Although it is known that both Apc and Apc2
are able to regulate Wnt signaling,12–14 and that this pathway
is frequently mis-regulated in many human cancers
including breast cancer,1,5–11 non-synonymous mutations
in these genes within mammary tumors are rare.5,6 The interplay
between Apc and Apc2 in this setting has never before been
explored.
Our model demonstrates that disruption of either Apc protein
alone fails to induce any overt abnormal phenotype within the
mammary gland, and reasserts the complexities that exist in
regulating Wnt transduction, tissue homeostasis and tumor
formation in this tissue. At the early time point analyzed, the
mammary architecture was disrupted following the combined
disruption of Apc and Apc2 despite the heterogeneous nature of
the Blg-Cre-driven gene recombination of APC. The mechanisms
that give rise to this disruption have not been fully elucidated,
although many Wnt-independent roles for APC have been
implicated in tumorigenesis (reviewed in refs56–58). However, in
addition to these potential Wnt-independent mechanisms, nuclear
β-catenin was observed in discrete areas of the gland and subtle
activation of Wnt signaling could remain a contributing factor for
the phenotype observed. Furthermore, upon aging, only mice
possessing disruption of both Apc proteins displayed retarded
survival and the appearance of tumors, which also displayed areas
of nuclear β-catenin.
Thus, our ﬁndings highlight the notion that the relative levels of
both proteins could be important in the pathogenesis of murine
breast tumors and, by inference, potentially for the development
of triple-negative breast cancers in humans, a subtype with a
particularly poor prognosis.59 Further, other contrasts and parallels
between this model and human disease can provide important
insights into the factors driving human mammary tumorigenesis
through the loss of the APC proteins.
Figure 5. Mammary tumors display areas of Wnt activation. Serial sections of tumor tissue were stained with H&E and β-catenin, cMyc and
CD44 antibodies. β-Catenin displayed a heterogeneous pattern with numerous cells exhibiting upregulation/nuclear expression. Both cMyc
and CD44 were expressed in the majority of cells demonstrating tumors are Wnt activated (top and bottom images scale bar, 50 μm; middle
images scale bar, 100 μm).
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Figure 6. Characterization of APC and APC2 copy number status in human breast cancer. (a) Human breast cancers from METABRIC and TCGA
array data sets, classiﬁed according to APC and APC2 copy number status, and subsequent association with breast cancer subtypes. (b)
Correlation of Wnt signaling target gene expression levels in samples classiﬁed according to APC and APC2 copy number status. (c) Kaplan–
Meier of breast cancer patients from METABRIC, classiﬁed according to APC and APC2 copy number status.
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MATERIALS AND METHODS
Mice
All animal procedures were conducted in accordance with institutional
animal care guidelines and UK Home Ofﬁce regulations. Previously
described Blg-Cre, Apcﬂ/ﬂ alleles30 and Apc2−/− mice29 were interbred and
maintained on a mixed C3H/C57BL6 genetic background. All animals were
genotyped by PCR analysis of DNA extracted from ear mark clippings. For
the aged cohorts, the end point was reached if general health visually
deteriorated or if mammary tumors arose and surpassed a set size (1.5 cm
diameter), blistered or restricted movement occurred.
Mammary gland whole mount
Whole mammary glands were dissected, washed three times with 1X
phosphate-buffered saline (PBS; Sigma-Aldrich Company Ltd., Dorset, UK)
following ﬁxation in 4% PFA for 2 h, then left in carmine alum solution (1 g
carmine (Invitrogen/Thermo Fisher Scientiﬁc, Loughborough, UK), 2.5 g
aluminum (Sigma-Aldrich Company Ltd.) in 500 ml distilled water) on a
rocker overnight. Glands were then washed again three times with 1X PBS,
dehydrated in increasing concentrations of ethanol and placed in xylene for
2 h to clear fat. Glands were then mounted on slides using glycerol. Stained
whole mounts were illuminated with a Leica CLS50X light source (Bruton,
UK) and visually analyzed under Olympus SZX12 low-magniﬁcation stereo
microscope (Southend-on-Sea, UK). Pictures were taken with Olympus
C4040ZOOM 4.1 megapixel digital camera. Branching events (bifurcation)
within the mammary gland was scored on n=3 glands for each genotype as
previously described60 and ducatal thickness of 30 ducts within each gland
(n=3 for each genotype) was measured as described.61
LacZ staining of whole mount mammary glands
Mammary whole mounts were ﬁxed then stained using X-Gal staining
solution: 1 mM MgCl2 (Sigma-Aldrich Company Ltd.), 3 mM potassium
ferricyanide (Sigma-Aldrich Company Ltd.), 3 mM potassium ferrocyanide
(Sigma-Aldrich Company Ltd.) in 1X PBS. The solution was stored in a tinfoil
wrapped bottle at − 20 °C and stock X-Gal solution (5% in dimethylforma-
mide, Promega, Southampton, UK) 0.02% was added immediately before
staining. The tissue was incubated with the staining solution overnight or
until the sufﬁcient level of staining was achieved at 37 °C. Once stained,
tissues were washed with 1X PBS and ﬁxed with formalin to avoid further
staining. Stained whole mounts were illuminated with Leica CLS50X light
source and visually analyzed under Olympus SZX12 low-magniﬁcation
stereo microscope. Pictures were taken with Olympus C4040ZOOM 4.1
megapixel digital camera.
Tissue sections and IHC
To prepare sections, mammary glands and tumors were ﬁxed in 4%
paraformaldehyde for 2 h or overnight, respectively, and then transferred
to 70% ethanol. Tissues were dehydrated, embedded in parafﬁn and
sectioned at 5 μm using a Leica RM2135 microtome. Sections were later re-
hydrated and either stained with hematoxylin and eosin (H&E) then
mounted or stained using IHC.
IHC visualization using DAB
Antigen retrieval was achieved by heating slides in a microwave in 1X
citrate buffer (LabVision, Thermo Scientiﬁc, Loughborough, UK) for
2 × 7 min (850 W). Slides were then left to cool in the solution for 30–
60 min. Slides were then washed in dH2O for 5 min followed by 2× 5-min
washes in washing buffer (1X tris-buffered saline (Sigma-Aldrich Company
Ltd.) in dH2O with 0.1% (v/v) TWEEN-20 (Sigma-Aldrich Company Ltd.)).
Endogenous peroxidases were blocked by incubating tissue sections with
hydrogen peroxide (Sigma-Aldrich Company Ltd.) or a commercial
peroxidase blocking solution (Envision+ Kit, DAKO, Ely, Cambridgeshire,
UK). Slides were then blocked with a suitable serum for 1 h at room
temperature followed by an incubation period with primary antibody.
Antibodies used were anti- Ki-67 (Vector Laboratories Ltd., Peterborough,
UK), Cleaved caspase-3 (Cell Signaling Technology, Danvers, MA, USA),
β-catenin (BD Transduction Laboratories, BD Biosciences, Oxford, UK), cMyc
Santa Cruz Biotechnology Inc. (Dallas, TX, USA) and CD44 (BD Pharmigen,
BD Biosciences). Following primary incubation, slides were incubated with
a suitable horseradish peroxidase-conjugated secondary antibody (Envi-
sion+ Kit, DAKO), and either visualized using 3,3'-diaminobenzidine (DAB)
(Envision+ Kit, DAKO) or the signal was ampliﬁed using ABC (Vectastain ABC
kit, Vector Laboratories Ltd.) ﬁrst then visualized with DAB. Sections were
counterstained with Mayers Hemalum (RA Lamb, Thermo Scientiﬁc) then
mounted using DPX mounting medium (RA Lamb, Thermo Scientiﬁc) ready
for imaging on an Olympus BX41 light microscope. When required, the
proportion of DAB-positive epithelial cells was counted microscopically,
nX3 samples for each genotype, and at least 2000 cells counted per sample.
IHC visualization using ﬂuorescence
For ﬂuorescent IHC, slides were processed as above up until the
endogenous peroxidase activity block stage. This step was excluded. The
serum block ((DAKO) or bovine serum albumin (Sigma-Aldrich Company
Ltd.)) was applied for an incubation time of 30 min followed by an
incubation period with primary antibody. Primary antibodies used were
anti-APC2 (Zymed, Thermo Fisher, Thermo Scientiﬁc), β-glactosidase
(Millipore, Sigma-Aldrich Company Ltd.), APC (Santa Cruz Biotechnology,
Inc.), CK5 (Abcam), CK8 (Abcam), Zo-1 (Zymed, Thermo Fisher, Thermo
Scientiﬁc), E-cadherin (BD Transduction Laboratories, BD Biosciences) and
β-catenin (BD Transduction Laboratories, BD Biosciences). Some slides
were double labeled using two primary antibodies and two corresponding
ﬂuorescently labeled secondary antibodies. Care was taken when selecting
antibodies to avoid cross-reactivity. Exposure to daylight of the secondary
antibody solution and stained sections was kept to a minimum to avoid
photo-bleaching. The slides were incubated with secondary antibodies
(suitable Alexaﬂuor 488 and/or Alexaﬂuor 594 (Invitrogen)) for 1–2 h.
Following the ﬁnal wash with wash buffer after incubation with the
secondary antibodies, slides were washed in 1X PBS (Invitrogen) and
mounted without dehydration using Vectashield hardset mounting
medium with DAPI (DAPI labels nuclear material blue) (Vector Laboratories
Ltd.). Slides were kept in the dark at 4oC and imaged within 2 weeks.
Images were taken using an Olympus BX61 with correct ﬁlters and lamp for
detecting ﬂuorescent probes.
Bioinformatics analysis
The METABRIC54 data were acquired from the European Genome-Phenome
Archive (EGAD00010000164) and normalized as described previously.62 The
TCGA55 clinical and RNASeqV2 data were obtained from the TCGA Data Portal.
For the METABRIC data, triple-negative status was deﬁned by IHC of ER and
HER2. For TCGA data, the IHC status of ER, HER2 and PR was used. Raw
Affymetrix SNP 6.0 microarray data were processed using PennCNV-Affy.63
Copy number data were obtained using the allele-speciﬁc copy number
analysis of tumors (ASCAT) algorithm. Tumors with loss of APC and APC2 were
identiﬁed and their pathophysiological classiﬁcation noted.
ABBREVIATIONS
APC, adenomatous polyposis coli; H&E, hematoxylin and eosin; IHC,
immunohistochemistry; Wt, wild type.
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